3'-deamino-3"-4'-anhydro-[2"(S)-ethoxy-3"(R)-hydroxy-4"-morpholinyl] doxorubicin | 1377918-03-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 蒽环类药物
• 英文名称: 3'-deamino-3"-4'-anhydro-[2"(S)-ethoxy-3"(R)-hydroxy-4"-morpholinyl] doxorubicin
• 英文别名: (7S,9S)-7-[[(2S,4R,6S,7S,9R,10S)-10-ethoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
• CAS: 1377918-03-0
• 化学式: C₃₃H₃₇NO₁₃
• 分子量: 655.656
• InChiKey: ZQIJOKWZHRCACW-SQMQQUATSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  47
• 可旋转键数：
  7
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  191
• 氢给体数：
  4
• 氢受体数：
  14

反应信息

• 作为反应物：
  描述：

  3'-deamino-3"-4'-anhydro-[2"(S)-ethoxy-3"(R)-hydroxy-4"-morpholinyl] doxorubicin 、 在 sodium periodate 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 以12 %的产率得到
  参考文献：
  名称：

  ANTHRACYCLINS AND CONJUGATES THEREOF

  摘要：

  The invention concerns analogues of nemorubicin as well as PNU-159,682 with a range of substituents other than 2"-0Me on the morpholino ring that beneficially affected the toxicity of the toxin over the molecules with the 2"-0Me group. In addition, it was found that PNU variants with modified 2"-O-alkyl chain show enhanced tolerability in vivo. Thus, by modification of the 2"-O-alkyl group, ADCs were generated with carefully tailored potency and tolerability to improve the administered dose in patients. The invention thus concerns compounds according to structure (1) and conjugates therewith, as well as pharmaceutical compositions and methods of targeting tumour cells and treating cancer.

  公开号：

  WO2024038065A1
• 作为产物：
  描述：

  在 咪唑 、 三聚氯氰 、 四丁基氟化铵 、 碘 、 sodium methylate 、 sodium acetate 、 potassium carbonate 、 N,N-二异丙基乙胺 、 间氯过氧苯甲酸 、 三苯基膦 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 丙酮 、 乙腈 为溶剂， 反应 103.7h， 生成 3'-deamino-3"-4'-anhydro-[2"(S)-ethoxy-3"(R)-hydroxy-4"-morpholinyl] doxorubicin
  参考文献：
  名称：

  ANTHRACYCLINS AND CONJUGATES THEREOF

  摘要：

  The invention concerns analogues of nemorubicin as well as PNU-159,682 with a range of substituents other than 2"-0Me on the morpholino ring that beneficially affected the toxicity of the toxin over the molecules with the 2"-0Me group. In addition, it was found that PNU variants with modified 2"-O-alkyl chain show enhanced tolerability in vivo. Thus, by modification of the 2"-O-alkyl group, ADCs were generated with carefully tailored potency and tolerability to improve the administered dose in patients. The invention thus concerns compounds according to structure (1) and conjugates therewith, as well as pharmaceutical compositions and methods of targeting tumour cells and treating cancer.

  公开号：

  WO2024038065A1

文献信息

• US8470984B2
  申请人：——

  公开号：US8470984B2

  公开（公告）日：2013-06-25